Clinical Pharmacology of a New Antithrombotic Agent, Ticlo

Abstract

A new antithrombotic agent, ticlopidine was administered to 6 healthy volunteers to investigate its effects on platelet function and blood coagulation as well as its safety.No problem was noticed in the safety of the drug when 500 mg was orally administered every 12 hours for 3 days. Blood concentration of the drug reached the peak level 2 hours after administration and it was not detected in blood 8 hours after administration. It was observed that ticlopidine exerted longlasting suppressive effect on platelet aggregation and adhesiveness, but it did not show any effect on the blood clotting and fibrinolysis systems.